According to a Monday NBC News report , the embattled organization - which lost its USA funding over its mismanagement of the COVID-19 crisis - announced that the drug may cause potential dangers in patients and is choosing to "err on the side of caution" by temporarily ceasing trials.
The ONS cautioned that the VE Day bank holiday weekend could have contributed to the low death count two weeks ago, but it follows a falling trend throughout May. It also added that deaths occur on average four days before they are registered. In the week ending 15 May there were 4,385 more deaths in England and Wales than would historically happen in that week of the year.
A randomized, double-blinded, placebo-controlled phase 2 trial of the Ad5-nCoV vaccine has been initiated in Wuhan to determine whether the results can be replicated, and if there are any adverse events up to 6 months after vaccination, in 500 healthy adults-250 volunteers given a middle dose, 125 given a low dose, and 125 given a placebo as a control.
The WHO has launched a review of the data it has in hand from the chloroquine and hydroxychloroquine arms in SOLIDARITY, but will continue dosing patients in the other arms that are testing remdesivir, AbbVie's HIV drug Kaletra (lopinavir/ritonavir) and interferon beta-1a.
Erck , CEO of Novavax. The problem seen in this early data is that subjects with high levels of pre-existing immunity to Ad5 seemed to show significantly reduced antibody and T-cell responses to the vaccine. USA president, Donald Trump, has said the USA would start mass production of any vaccines developed before they are fully approved so that they can be quickly distributed once rubber-stamped.
Multiple studies have found the drug can actually make symptoms worse, and increase the death rate of COVID-19 among patients. He further pointed out that the concern related only to the use of hydroxychloroquine and chloroquine for Covid-19, adding that the drugs are accepted treatments for people with malaria and auto-immune diseases.